Home › Chronic Kidney Disease › New York › Buffalo
Chronic Kidney Disease clinical trials in Buffalo, NY
3 studies for Chronic Kidney Disease are looking for participants at sites in and around Buffalo (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
RecruitingPhase 2
- Rochester Clinical Research - Buffalo, Buffalo
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
RecruitingPhase 3
- Research Site, Buffalo
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
RecruitingPhase 3
- Research Site, Buffalo
About Chronic Kidney Disease
If your kidneys are damaged and can't filter blood easily, then you may suffer from chronic kidney disease (CKD). Read about the treatments available
More about Chronic Kidney Disease on MedlinePlus
Chronic Kidney Disease trials in other cities
- New York City, NY16 studies
- Houston, TX15 studies
- Philadelphia, PA15 studies
- Boston, MA15 studies
- Dallas, TX15 studies
- Chicago, IL12 studies
- Orlando, FL11 studies
- Atlanta, GA10 studies
- Kansas City, MO9 studies
- Durham, NC9 studies
- San Antonio, TX8 studies
- Albuquerque, NM8 studies
Other studies in Buffalo
- Cancer (all types)19 studies
- Acute Myeloid Leukemia19 studies
- Non-Small Cell Lung Cancer18 studies
- Lung Cancer16 studies
- Breast Cancer16 studies
- Ovarian Cancer13 studies
- Prostate Cancer11 studies
- Metastatic Cancer11 studies
- Multiple Myeloma10 studies
- Melanoma10 studies
- Obesity9 studies
- Burkitt Lymphoma8 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.